Search Results
Your search for ,maY matches 16623 pages
Showing 10851 - 10900The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests
In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
A Space to Heal
We pass them every day on our way to the hospital, the street dwellers of our town in India. Their home consists of a plastic sheet suspended between four poles on the pavement. One day, two women sat under the plastic sheet in happy conversation. It had rained heavily the previous night, and I...
ASCO Supports Recent Tobacco Legislation
On August 8, the U.S. Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate e-cigarettes, cigars, hookahs, and pipe tobacco took effect. In May, ASCO applauded the FDA for exercising its congressionally mandated authority to regulate e-cigarettes as a crucial step in ...
Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer
When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
A Helping Hand, Just in Time: The ASCO Guideline for Managing Chronic Pain in Adult Cancer Survivors
With impeccable timing, as well as considerable forethought and planning, Dr. Paice and colleagues have produced a superb evidence-based guideline on “Management of Chronic Pain in Survivors of Adult Cancers.”1 (See this issue of The ASCO Post.) This summary of well-informed and thoroughly...
ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers.1 The guideline was based on literature review by an expert panel,...
Amelie G. Ramirez, DrPH, Receives AACR Distinguished Lecture on the Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen, honors an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or...
Which Factors Influence Radiotherapy for Brain Metastases?
The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...
Clinical Trials Actively Recruiting Patients With Early Breast Cancer
Pilot Study Title: Pilot Trial of an Implantable Microdevice for in Vivo Drug Sensitivity Testing in Patients With Early-Stage, HER2-Positive, or Triple-Negative Breast Cancer Receiving Neoadjuvant Therapy Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators:...
Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer
Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...
Daratumumab Plus Bortezomib/Dexamethasone: Changing the Treatment Paradigm in Relapsed or Refractory Myeloma
The CD38 antigen was first recognized on normal and abnormal plasma cells over 3 decades ago. Indeed, this antigen was originally classified as T10, as it was the tenth antigen described on T cells. Its distribution of expression included activated B and T cells, natural killer cells, leukocytes,...
Why Care About the Caregivers?
Caregivers of patients with cancer provide invaluable health-care services, but they are an underserved and undervalued group, with many unmet needs. Early palliative care may provide important benefits to these often tireless individuals, according to J. Nicholas Dionne-Odom, PhD, RN, ACHPN, of...
Benefits of Early Palliative Care Interventions Extend Beyond the Patient
A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...
Palliative Care: Let’s Use the Tools We Already Have
Clinicians and researchers in the field of palliative and supportive care are enjoying the recognition the field is now receiving and expecting the future to be ripe with opportunity. But one thought leader in this specialty had a suggestion for attendees at the 2016 Palliative Care in Oncology...
Pearls for Managing Immune-Related Toxicities
With checkpoint inhibitors in frequent use, clinicians strive daily to balance the efficacy and toxicity of these treatments. At the 2016 Palliative Care in Oncology Symposium, Lynn M. Schuchter, MD, FASCO, the C. Willard Professor of Hematology-Oncology at the University of Pennsylvania,...
Immunotherapy Brings Unique Challenges for Clinicians
The advent of immunotherapies has created a number of interesting challenges for oncology providers. At the 2016 Palliative Care in Oncology Symposium, specialists in the field tackled these issues. “There is a lot of newness to how we approach patient care with immunotherapies on board,” said...
Why Curing Cancer Will Take Decades
This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...
Bridging the Gap in Oncology Care
The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...
COA Releases 2016 Community Oncology Practice Impact Report
The Community Oncology Alliance (COA) released the 2016 Community Oncology Practice Impact Report today, which tracks the changing landscape of cancer care in the United States. It documents a 121% increase in community cancer clinic closings and a 172% increase in consolidation into hospitals...
Study Finds TP53 and MDM2 Alterations Linked to Cisplatin Resistance in Advanced Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Bagrodia et al found that alterations in TP53 and MDM2 were associated with cisplatin resistance and poorer outcome in patients with advanced germ cell tumors. Actionable alterations were found in a high proportion of cases of cisplatin...
Update on Neoplastic Hematology: Review of Recent Clinical Trials
Here is a brief look at the study findings and clinical implications of several recent clinical trials on newer treatment options in neoplastic hematology. Attention is focused on several types of leukemia, Hodgkin lymphoma, and multiple myeloma. Leukemia Clinical Trial: INO-VATE ALL phase III...
Prehabilitation and Rehabilitation May Improve Work-Related Outcomes in Cancer Survivors
In August 2016, the Healthcare Delivery Research Program of the Division of Cancer Control and Population Sciences at the National Cancer Institute convened a group of experts in a variety of fields to identify a research agenda for optimizing employment outcomes among cancer survivors. A core...
AACR’s Cancer Progress Report Hails Research Advances and Details Challenges Ahead
Although research advances in more effective therapies and diagnostics and improved screening technology over the past 2 decades have led to a 23% reduction in the cancer death rate in the United States, saving nearly 2 million lives,1 cancer remains the second leading cause of death after heart...
Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
Study Finds Pneumonitis Associated With Anti–PD-1/PD-L1 Antibody Treatment
In a two-institution experience reported in the Journal of Clinical Oncology, Naidoo et al identified the incidence of pneumonitis occurring in patients receiving anti–PD-1/PD-L1 (programmed cell death protein 1/ligand 1) monoclonal antibody as monotherapy or combined with anticytotoxic...
FDA Approves Osimertinib Blood-Based T790M Companion Diagnostic Test
On September 29, the U.S. Food and Drug Administration (FDA) approved a blood-based companion diagnostic for osimertinib (Tagrisso). The companion diagnostic for osimertinib is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample ...
ASTRO 2016: Extremely Hypofractionated Radiation Therapy Shows Promising Toxicity Results for Intermediate-Risk Prostate Cancer
For men with intermediate-risk prostate cancer, side effects at 2 years following radiation therapy were comparable for extremely hypofractionated treatment, which was delivered in 7 fractions across 2.5 weeks, and conventional treatment of 39 fractions across 8 weeks, according to research...
ASTRO 2016: Intervention Closes Racial Gap and Improves Treatment Rates for Early-Stage Lung Cancer
Enhanced, culturally competent communication with early-stage lung cancer patients can narrow racial gaps in curative treatment completion and increase treatment rates for all races, according to research presented by Manning et al at the 58th Annual Meeting of the American Society for Radiation...
ASTRO 2016: Stereotactic Radiosurgery Decreases Rate of Postoperative Local Recurrence for Brain Metastases
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence, but shows no positive difference in terms of overall survival or distant brain metastases rates when compared to observation alone following surgical...
ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments
High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...
ASTRO 2016: Hypofractionated Radiation Therapy May Halve Treatment Time for Lung Cancer Patients With Poor Performance Status
For patients with stage II and III non–small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation, hypofractionated radiation therapy results in similar overall survival and progression-free survival rates, limited severe side effects, and shorter...
ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...
ASTRO 2016: Radiation Boost Reduces Local Tumor Recurrence for Patients With DCIS Following WBRT
A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with ductal carcinoma in situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research ...
ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
ASCO/ASTRO/SSO Develop Focused Guideline Update on Postmastectomy Radiotherapy
As reported by Recht et al in the Journal of Clinical Oncology, a joint ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) panel has developed a focused guideline update of the ASCO guideline on postmastectomy radiotherapy. A recent Cancer Care Ontario...
ASTRO 2016: Unmet Need for Radiation Therapy Found Among Nearly Half of Eligible Cancer Patients in Nine Developing Countries
Although approximately 50% of cancer patients in developing countries need radiation therapy to treat their disease, up to half of these patients do not have access to it, according to research presented by Rosenblatt et al at the 58th Annual Meeting of the American Society for Radiation Oncology...
ASTRO 2016: Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients With Early-Stage Lung Cancer
Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) rose from roughly 40% to 60% over the past decade, concurrent with the increasing adoption of SBRT, according to research presented by Dalwadi et al...
Ratio of Certain Immune Cells in the Blood to Tumor Burden Correlated With Outcome for Melanoma Patients Treated With Pembrolizumab
Although some patients with melanoma experience durable responses to treatment with the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda), the majority of patients do not experience a durable clinical benefit from anti–PD-1 monotherapy, according to a study by ...
Combining AM0010 and Pembrolizumab Produced Antitumor Activity in Patients With Advanced Solid Tumors
A multibasket phase Ib study evaluating the clinical activity, tolerability, and antitumor activity of the cytokine-based immunotherapy AM0010 alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) has found that in monotherapy, objective responses to AM0010 were ...
Improved Event-Free Survival With Addition of Rituximab to Chemotherapy in B-Lineage Adult ALL
In the phase III GRAALL-2005 trial reported in The New England Journal of Medicine, Maury et al found that the addition of rituximab (Rituxan) to standard chemotherapy resulted in improved event-free survival in adult patients with B-lineage acute lymphoblastic leukemia (ALL). Study Details In...
Does Colonoscopy Screening in Older Adults Prevent Colorectal Cancer?
A large population-based observational study by García-Albéniz et al evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found the test reaped only a modest benefit in preventing colorectal...
Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...
10-Year Risk of Invasive Breast Cancer After Diagnosis of Atypical Ductal Hyperplasia by Needle Biopsy
The cumulative estimated risk of invasive breast cancer at 10 years after diagnosis of atypical ductal hyperplasia by core-needle biopsy was approximately 5%, according to a study reported by Menes et al in JAMA Oncology. The 10-year risk was 6.7% with atypical ductal hyperplasia diagnosed by...
Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk
In a new study, men who underwent vasectomy did not have an increased risk of prostate cancer, nor were they more likely to die from prostate cancer than men who did not receive this procedure. According to the researchers, this is the largest prospective study of vasectomy and fatal prostate...
Emily L. Sedgwick, MD, Receives Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism
Emily L. Sedgwick, MD, Associate Professor of Breast Imaging in the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center, has been named the 2016 recipient of the Ben and Margaret Love Foundation Bobby Alford Award for...
I’ve Survived Cancer for Over 71 Years
Even though I was just 3 years old when my symptoms first appeared, the memory is still fresh in my mind to this day, 71 years later. I had just come home from a friend’s birthday party and was sitting on the front patio steps immobilized by severe stomach pain. My parents said I was feeling ill...
Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances
Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...
